Karriere
am Klinikum & Medizinischer Fakultät
PhD student (f/m/d)
University Hospital Tübingen, Department of Medicine II, Research Group RNA-Immunotherapies, index number 6933
Part-time65 %
Limited: 3 years
Start of work:as soon as possible
Application deadline:01.01.2026
- Planning, implementing and performing research experiments
- Analysis, interpretation and presentation of research findings
- Contribution to grant writing, research reports and publications
- Scientific literature research and development of new ideas
- Diploma or Masters Degree (or equivalent) in biology, biochemistry, life sciences or related discipline
- Strong interest in RNA-based drugs
- Team-player attitude
- Ability to work independently
- Creativity and thinking outside the box are encouraged
- Excellent English skills (oral and written), German knowledge is prefered
- Experience in molecular biology techniques and practical skills in animal experimentation are welcome
Benefits
- Work in the diverse environment of a modern university hospital, which focuses not only on patient care but also on medical research and teaching
- A future-proof job and location, as well as attractive remuneration including a company pension scheme (VBL) and flexible working hours
- Subsidy for public transport tickets and attractive discounts on our employee offer platforms
- Structured onboarding phase, hospital-owned academy for developing professional, social and methodological skills
- Healthcare through a wide range of sports activities
The University Hospital of Tübingen is a leading center of German university medicine. Every year, around 75,000 inpatients and around 380,000 outpatients are treated. With over 11,000 employees, it is the largest employer in the region. The quality of patient care is certified with the KTQ seal of approval.
The research group of Dr.Dr.Haraszti focuses on the preclinical development of RNAi-based drugs to engineer therapeutic immune responses for several hematologic malignancies. We use state-of-the-art RNA technology equivalent to approved RNAi drugs. The overarching goal is transcriptionally repogram immune cells in order to increase efficacy and optimize safety of immunological cell therapies. The specific goal of this PhD position is to develop state-of-the-art tools to deliver advanced RNAi drugs to T cells in vivo.
Methods:
- Molecular Cloning
- Primary Immune Cell Culture
- QuantiGene assays
- Fluorescent Imaging
- Flow cytometry
- BSL2 gene technology work
- Animal work – immunocompromised mice.
For more information click here.
Mrs. Dr.Dr. Reka Haraszti
Index number: 6933
Including CV and cover letter
Application deadline: 01.01.2026
Index number: 6933
Including CV and cover letter
Application deadline: 01.01.2026
.png)
.png)
We offer remuneration in accordance with TV-L (collective wage agreement for the Public Service of the German Federal States),
severely handicapped persons with equal qualifications are given preferential consideration.
Interview expenses are not covered.
Please note the applicable vaccination regulations.
